3 Reasons Potential Side Effects Trump Positive Phase 3 Data

Cardiovascular side effects might kill Intercept's chances for off-label use, killing OCA's chances to get established well ahead of Conatus Pharmaceuticals, Gilead Sciences and Isis Pharmaceuticals.

Mar 17, 2014 at 5:47PM

In its 10-K on Friday, Intercept (NASDAQ:ICPT) disclosed that patients with nonalcoholic steatohepatitis, or NASH, taking its liver drug obeticholic acid, or OCA experienced cardiovascular serious adverse events.

On Sunday, the biotech followed up with positive news that a phase 3 trial testing OCA in another liver disease, primary biliary cirrhosis, or PBC, was positive.

The 10-K news won the battle with shares trading down 12% today.

Expected
I'm not sure how damning the cardiovascular events were -- more on that in a bit -- but the positive data in PBC didn't help that much because the results were fairly expected, especially compared to Intercept's one-day jump of more than 500% in January when the biotech announced positive data in the NASH trial.

The phase 2 PBC trial completed in 2011 was highly statistically significant with a p-value of less than 0.0001. Or in other words, there was a 0.01% chance that the observed difference between OCA treatment and placebo happened because of chance alone. With more patients in the phase 3 trial, the likelihood of success was even higher.

The phase 3 trial, dubbed POISE, met its endpoint of reducing alkaline phosphatase and having a normal bilirubin level, biochemical markers used to diagnose the disease. A solid 47% of patients taking the high dose of OCA met the designated criteria compared to just 10% in the placebo group. A third group was tittered from a low dose to the high dose if the low dose wasn't working, which worked just as well with 46% of patients meeting the endpoint.

There's never a 100% certainty with drug regulators, but Intercept looks like it has the efficacy data to get OCA approved for PBC. Considering the current treatment, ursodiol, only works in up to half of the patients, there's plenty of unmet need, which tends to make regulators more lenient on safety issues.

Back to those potential side effects
Intercept disclosed that there were 10 cardiovascular severe adverse events in seven patients in its NASH trial that was stopped early in January because an interim peak at the data showed that OCA was working extremely well.

The number of events was higher in patients taking OCA compared to placebo, but the difference wasn't statistically significant. More than half of the patients in the trial were diabetics, who are more likely to undergo cardiovascular events so it's possible that OCA isn't causing the cardiovascular events. Unfortunately, Intercept didn't disclose the p-value, so we don't know how likely that the observed increase in cardiovascular events in the OCA group happened by chance alone.

There were two cardiovascular serious adverse events in the PBC trial -- one in the placebo and one in the titration group. For this trial, at least, the rate of cardiovascular events is actually lower for patients on drug since there were more patients on drug in the trial given the two dosing arms.

Off label use
Intercept isn't going to start its NASH trial until the first half of next year, so an approval is still a ways away. But doctors could use OCA off-label once it was approved for PBC given the unmet need in NASH -- there aren't any drugs approved for the disease, although Conatus Pharmaceuticals (NASDAQ:CNAT), Gilead Sciences (NASDAQ:GILD), and Isis Pharmaceuticals (NASDAQ:IONS) are working on drugs of their own.

We haven't seen the full phase 2 data in NASH, but it seems likely the efficacy data will be compelling considering the trial was stopped early. Unfortunately with cardiovascular events -- even if they might only be happening by chance -- doctors might be a little more cautious in prescribing OCA off label, potentially killing OCA's chances to get established well ahead of Conatus, Gilead and Isis.

You won't find a liver disease with a $14.4 trillion market.
The key to investing in hyper-growth markets is to find a small-cap "pure-play" and then watch as it grows in explosive fashion within its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 trillion industry. Click here to get the full story in this eye-opening report.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers